AstraZeneca (AZN) Lower, Loses Certain CRESTOR Patent Decision
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca plc (NYSE: AZN) is ticking lower following headlines that it lost a ruling over 2018 and 2022 CRESTOR patents. Shares are down 0.7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
- 'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
- Priovant enrolls first patients in Phase 3 cutaneous sarcoidosis trial
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
